BDAZ

In the past you and other qualified posters  have written that if the 3 point Mace events are not conclusive, or do not provide a sound basis for trial acceptance, the number of trial patients may have to be increased to 3600 from 2400. If I am incorrect on this point, please correct me. 

Can you tell me what the probability is that this may occur, the estimated increased trial costs to expand the trial to 3600 patients and dose another 1,200 patients, approximateley when and by whom will this be determined, and how much longer will that extend the Phase III trial? 

Thank You

Chicagoest